Gilde Healthcare

Our focus is on opportunities that are beyond proof of concept and poised for more significant development and growth in the Medical Device, Life Science Tool, Diagnostic and Digital Health sectors. Why Gilmartin Capital? The investing landscape is long on capital and short on insight. Our value extends beyond capital. We possess extensive domain expertise in areas such as strategy, market assessment, and capital markets advisory. Our passion is to avail our experience and network to help you solve problems, drive scientific discovery, help patients and grow. For over two decades, we have amassed a propriety expert network consisting of key opinion leaders across multiple therapeutic verticals and technical specialties, and best-in-class operators in various operational, scientific, and financial areas. In fact, the majority of our fund capital comes from operators like you. The founding partners have decades of experience analyzing and advising healthcare technology companies. We do the math! We want to help you advance your vision.

Founded over 20 years ago, Kaiser Permanente Ventures has developed into a national leader in strategic venture investing in healthcare. In partnership with Kaiser Permanente and our limited partners, the KPV team has invested in and helped support over 65 companies, representing some of the most important innovations in healthcare delivery over this time period. We’ve achieved these successes through deep engagement within KP and across our investment partners, leveraging the tremendous insights that come from those leading our healthcare systems and care delivery to identify the most pressing needs within healthcare and select the innovations that most effectively address those opportunities. Together with our partners, KP and KPV represents22,000+ clinicians and over 180,000 healthcare employees 38+ acute care hospitals and over 600 other healthcare-related facilities Approximately $65 billion in annual operating revenue Largest U.S. single comprehensive electronic medical record system Leading evidence-based care delivery mode Our fund targetsHealth Information Technology (Enterprise Solutions) Digital Health Healthcare Services Medical Devices Diagnostics and Precision Medicine

AGP is a fund management company spun out from EDBI, a state-owned fund in Singapore, with former senior employees as founders. The fund will continue to have close affiliation to EDBI providing unique opportunities for collaboration and investments. We are raising a dedicated healthcare fund (“AGP Healthcare Fund” or “AGPHC”) to build on our successes at EDBI and to capture new opportunities. Our partners have a credible reputation built on years of working together at EDBI and having strong domain expertise in healthcare, with extensive network and deep linkages to the Singapore, regional, and global biomedical and healthcare ecosystem. Our investment areas* include medtech & manufacturing, services & others, healthtech, and biotech & therapeutics. At AGP Healthcare Fund, we focus on investing in growth-stage companies (Series C to pre-IPO) (~75%) and venture-stage companies (Series A and B) (~25%). Our unique position in serving both SEA/Asia and global markets is driven by our belief that SEA is an emerging innovation hub with tremendous potential to build differentiated and valuable healthcare companies. We see opportunities for healthcare companies to capitalize on the Asian growth momentum by leveraging Singapore's position as a nexus between the East and the West. With our global insights and proven track record, we provide valuable guidance and advice to founders in expanding their businesses globally. Investment areasMedtech & Mfg, Services & Others: minimally invasive devices, medical equipment manufacturing & distribution, surgical robotics, diagnostics, healthcare services, new modalities CRDMOs, life science equipment & consumables, drug manufacturing & distribution Healthtech: remote patient monitoring, virtual care delivery, digital health platform, workflow automation, healthcare analytics, AI in healthcare imaging, digital therapeutics, chronic disease management Biotech & Therapeutics: cell & gene therapy, RNA therapeutics, AI drug discovery, targeted therapy & immunotherapy, gene editing tools & infrastructure, regenerative medicine & tissue engineering, and life science tools

At Flare Capital, we do more than simply provide capital for early stage and emerging healthcare technology companies. We partner with the most creative and passionate entrepreneurs aspiring to reinvent the business of healthcare. Together we work to build transformational companies that will profoundly improve the delivery and quality of healthcare while reducing costs. Our Team In 2014, Michael and Bill came together with the vision to build the leading dedicated healthcare technology venture capital firm. Both had started successful venture firms earlier in their careers and had a shared perspective on what the market now needed. As the “business of healthcare” is being transformed, there are significant opportunities to create important and enduring new healthcare technology companies. Given the complexity of this sector, a focused investment strategy with an experienced, committed team is required, and thus Flare Capital was launched. The firm is comprised of a number of proven healthcare technology investors with both deep industry knowledge and venture capital experience alongside accomplished operating executives of leading healthcare organizations. Our Executive Partners have substantial operating experience and our Industry Advisory Board includes many of the brightest healthcare minds with unique perspectives from across the industry. Together they provide critical insights and points of connectivity for our team at Flare Capital and are a tremendous resource for our entrepreneurs. Our Flare Scholars are professionals from preeminent healthcare companies and students from academic institutions across the country who scout interesting people and investment opportunities for us while learning about venture capital. Our Investors We have hand-assembled some of the most successful healthcare organizations, leading family offices, pension funds and investment companies as investors. At Flare Capital, we are privileged to partner with and have unparalleled access to leading innovative healthcare providers, payers, medical device companies, laboratory services provider, healthcare retailer, and one of the largest owners of healthcare campuses. Our investors have an enormous footprint in healthcare and are on the forefront of healthcare innovation. Our Approach We invest across the United States, recognizing that healthcare technology innovation is occurring in many cities around the country. While we consider ourselves principally early stage investors, we are full lifecycle investors. We partner with our entrepreneurs across the entire journey of company building. We are committed to our entrepreneurs and to being their first call, as we work closely and patiently through all strategic issues confronting our companies, maximizing their probability of success. In particular, we are very focused on assisting with recruiting and securing early customer validation and revenues. Starting and then scaling a successful healthcare technology company is hard. Careful and thoughtful financing strategies need to map to detailed product development timelines and other commercial milestones. We closely collaborate with our entrepreneurs to ensure that they have critical access to the best resources as the business scales. We relentlessly strive to be a true partner and to deliver extraordinary value to our entrepreneurs to enable them to build market leading, transformational businesses.

We have nearly 300 companies in our portfolio including over 30 that we started from scratch. Our global portfolio is spread across the Americas, Europe, and Asia. Over four and a half billion dollars under management. Big ideas need big investments. We have the heft and history to make a significant impact in the world. Healthcare: We create and invest in leading companies in therapeutics, medtech, and health IT & services. Technology: We've been partnering with fearless founders for over 50 years.

RA Capital Management is a multi-stage investment manager dedicated to company formation and evidence-based investing in healthcare and life science companies developing drugs, medical devices, diagnostics, services, and research tools. The firm’s portfolio of private and public companies spans the globe and most therapeutic areas across all stages from discovery through commercialization. We are committed to fostering diversity at RA, in our portfolio companies, and in the broader biotech community. Who We AreOur flexible strategy allows us to provide seed funding to startups and lead private, IPO, and follow-on financings for our portfolio companies, thereby driving value creation from idea inception through commercialization. At RA Capital’s core is its TechAtlas research division, a scientifically trained team that maps out competitive landscapes to put data into context, identify breakthroughs, and originate conviction in new ideas. TechAtlas provides market intelligence and, technical diligence, and other resources to both our internal Investment Team and our portfolio companies. The team’s understanding of industry best practices is derived from an extensive collection of case studies documenting the impact of clinical trial design, partnership structures, and public market dynamics. Beyond CapitalRA Capital offers its portfolio companies much more than capital to help them grow, make decisions, and succeed. We:Serve on boards of private and public companies and host board meetings at our offices Help recruit executives and board members Provide access to TechAtlas maps and expertise Prioritize indications and targets based on their feasibility and value given current scientific knowledge, unmet needs, and emerging competition Monitor for new applications and complementary technologies Create custom maps that lay out a company’s competition and unrealized opportunities Provide extra analytical bandwidth across our large team (e.g., analyze literature, provide insights from scientific and investor conferences) Assist with grant writing and preparation of scientific publications Interview clinicians and key opinion leaders (KOLs) Host advisory boards Facilitate partnership or acquisition discussions with larger companies Help design (or redesign) a corporate slide deck or website, leveraging in-house writing and graphics teams Make introductions to other investors Anchor subsequent financings and set the pace for closing Help select bankers for financings and M&A We also provide a growing suite of Innovator Resources to the broader ecosystem, with more hands-on support for our portfolio companies, management teams, and boards. These resources include: a comprehensive reference guide to conducting successful biotech board meetings; a data-driven guide to how to conduct a logical IPO based on first principles of price discovery and shareholder alignment; and a roadmap for how to convey your company’s unique Equity Value Proposition to employees (because they are also your investors). We’re available to coach you through a pitch, provide feedback on a deck, and partner with you to refine strategy or messaging at every stage. Additionally, we helped to found and continue to support No Patient Left Behind, a non-profit dedicated to promoting affordability of today’s medicines and the development of better ones. More specifically, NPLB advocates for insurance reforms that would allow all patients to afford the treatments they need, draws attention to the full societal value of all medicines and the merits of ensuring that all drugs go generic without delay, and educates lawmakers and the public about the workings of the biomedical ecosystem to protect it against misguided policies. Translation & HuntingRA Capital offers Executive-In-Residence (EIR) and venture partner programs for experienced professionals seeking thought partners. We welcome experienced drug hunters searching for technologies/candidates and looking to start new companies to collaborate with our team, explore the capabilities of our in-house incubator, and take advantage of the breadth and depth of our TechAtlas platform. RAVen, our in-house incubator, provides a collaborative platform for drug hunters and company builders to explore both the novel and the re-imagined. Discoveries and improvements in chemistry, molecular and cellular biology, and materials science create novel capabilities that may address unsolved challenges. Our understanding of fundamental biology is constantly evolving, revealing new applications for existing technologies and partially-developed drug candidates. Programs we consider worthwhile may form the basis for a new venture. We believe that when a business proposition is framed correctly, the capital markets have adequate resources and understanding to fund proper experimental design and solution development without forcing companies to cut corners. Furthermore, we have collaborated extensively with other funds that share our philosophy to enable ambitious and capital-intensive endeavors. Our ValuesWe at RA Capital are introspective and deliberate about the ways in which we engage with each other and those outside our firm. Our values represent a set of clear parameters by which we create working relationships founded on trust, collaboration, diligence, and integrity.We originate conviction. We do not borrow it from others. We expect and strive to inspire the best in everyone. We embrace the unfamiliar. We do not let convention stand in the way of what is right. We learn collaboratively. We have a bias for action. We are persistently curious and humbled by what is left to learn. We are data-driven and challenge assumptions. We preserve the ability to change our mind. We admit our mistakes and share lessons learned. We address the elephant in the room. We value our relationships and are positive, respectful, and open-minded. We take fun seriously.